Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Stroke guideline supports expanded alteplase use.

Traynor K.

Am J Health Syst Pharm. 2013 Mar 15;70(6):474, 476, 478. doi: 10.2146/news130021. No abstract available.

PMID:
23456396
2.

Alteplase for stroke. American Heart Association explains how guidelines were formulated.

Faxon D.

BMJ. 2002 Jun 29;324(7353):1581; author reply 1581. No abstract available.

PMID:
12092606
3.

Commentary on NICE guidelines for alteplase for the treatment of acute ischaemic stroke.

Lindley RI.

Heart. 2007 Dec;93(12):1617-8. No abstract available.

4.

Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance.

Chung H, Refoios Camejo R, Barnett D.

Heart. 2007 Dec;93(12):1616-7. Erratum in: Heart. 2008 Feb;94(2):229. Camejo, R R [corrected to Refoios Camejo, R].

5.

Tissue plasminogen activator approved for stroke.

Barber A, Gommans J.

N Z Med J. 2005 May 6;118(1214):U1432. No abstract available.

PMID:
15886728
6.

Alteplase is safe to use within existing treatment guidelines, says independent review.

Torjesen I.

BMJ. 2015 Jul 27;351:h4062. doi: 10.1136/bmj.h4062. No abstract available.

PMID:
26215777
7.

Emergency physician survey: recombinant tissue plasminogen activator for stroke.

Walsh M, Fromm G.

Ann Emerg Med. 2006 Mar;47(3):297. No abstract available.

PMID:
16492504
8.

Use of tissue plasminogen activator to treat acute ischemic stroke.

Alexandrov AW.

Crit Care Nurse. 2010 Oct;30(5):77-8. doi: 10.4037/ccn2010378. No abstract available.

9.

Doubts, fears and misconceptions. What is the future of thrombolysis in acute stroke?

Barber PA, Hill MD, Demchuk AM, Buchan AM.

Can J Neurol Sci. 2000 Nov;27(4):283-7. Review.

PMID:
11097516
10.

Thrombolytic therapy for patients with acute stroke in the ED setting.

Blank FS, Keyes M.

J Emerg Nurs. 2000 Feb;26(1):24-30. Review. No abstract available.

PMID:
10657792
11.

Alteplase for ischaemic stroke--much sooner is much better.

Saver JL, Levine SR.

Lancet. 2010 May 15;375(9727):1667-8. doi: 10.1016/S0140-6736(10)60634-4. No abstract available.

PMID:
20472152
12.

Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.

Lenzer J.

BMJ. 2002 Mar 23;324(7339):723-9. Review. No abstract available.

13.

A panoramic, practice-based view of intravenous alteplase 3-4.5 h after stroke.

Kasner SE, Levine SR.

Lancet Neurol. 2010 Sep;9(9):843-5. doi: 10.1016/S1474-4422(10)70169-1. Epub 2010 Jul 26. No abstract available.

PMID:
20667791
14.

[Thrombolytic therapy in stroke approved with reservation. Underlying evidence, practical guidelines and safety follow up].

Wahlgren NG.

Lakartidningen. 2004 Feb 19;101(8):674-7. Review. Swedish. No abstract available.

PMID:
15024940
15.

Can the therapeutic window for tissue plasminogen activator be extended to 6 hours after stroke onset?

Alexandrov AV.

Nat Clin Pract Cardiovasc Med. 2005 Jul;2(7):342-3. No abstract available.

PMID:
16265558
16.

Intravenous thrombolytic therapy for acute ischemic stroke.

Burberi F, Bruscoli M.

N Engl J Med. 2011 Sep 8;365(10):965; author reply 966-7. doi: 10.1056/NEJMc1108289#SA2. No abstract available.

PMID:
21899471
17.

Alteplase for stroke. Uncertainty remains about efficacy.

Mann H.

BMJ. 2002 Jun 29;324(7353):1581; author reply 1581. No abstract available.

18.

Alteplase for acute stroke revisited: the first 10 years.

Lyden PD, Lees KR, Davis SM.

Lancet Neurol. 2006 Sep;5(9):722-4. No abstract available.

PMID:
16914399
19.

Alteplase for stroke. Patients and doctors are being misled by promotional pressures.

Li J, Nathanson LA, Mills TJ, Netland KE, Paula R, Ragland D.

BMJ. 2002 Jun 29;324(7353):1581; author reply 1581. No abstract available.

PMID:
12092605
20.

Acute ischemic stroke: Not a moment to lose.

Miller J, Mink J.

Nursing. 2009 May;39(5):37-42; quiz 42-3. doi: 10.1097/01.NURSE.0000350755.49282.6a. Review.

PMID:
19395934

Supplemental Content

Support Center